Holen Sie sich die Stockscreener-App
5.44
3.37%
-0.19
Alpha Cognition Inc Aktie (ACOG) Neueste Nachrichten
Acetylcholinesterase Inhibitors Market is expected to reach - openPR
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory - Insider Monkey
Alpha Cognition sets new executive and director compensation By Investing.com - Investing.com Australia
Alpha Cognition sets new executive and director compensation - Investing.com India
Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions - Yahoo Finance
Institutions profited after Alpha Cognition Inc.'s (NASDAQ:ACOG) market cap rose US$12m last week but retail investors profited the most - Simply Wall St
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease - Business Wire
Acetylcholinesterase Inhibitors Market Size, Share, Industry - openPR
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) - Newsfile
Stonegate Capital Partners Initiates Coverage on Alpha Cognition's Innovative Alzheimer's Therapy ZUNVEYL - citybuzz -
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - The Manila Times
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - GlobeNewswire Inc.
Alpha Cognition to delist from Canadian Securities Exchange - MSN
Acetylcholinesterase Inhibitors Market: Industry Growth - openPR
Moves at FDA, NIH - BioCentury
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - BioSpace
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon - Verywell Health
Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch - TipRanks
Alpha Cognition Expands Leadership Team Ahead of Landmark Alzheimer's Drug Launch in 2025 - StockTitan
Top Dividend Stocks For Reliable Income In January 2025 - Simply Wall St
Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS - News & Insights
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - JCN Newswire
Alpha Cognition licenses ZUNVEYL in Asia and Oceania By Investing.com - Investing.com Canada
ACOG News Today | Why did Alpha Cognition stock go up today? - MarketBeat
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China - AOL
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - The Manila Times
Alpha Cognition licenses ZUNVEYL in Asia and Oceania - Investing.com India
China Medical System Secures Rights to Alzheimer’s Drug ZUNVEYL - TipRanks
Alpha Cognition Lands $44M ZUNVEYL Licensing Deal for Massive Asian Alzheimer's Market - StockTitan
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - Business Wire
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call - BioSpace
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Alpha Cognition files to sell 1.45M common shares for holders - MSN
Alpha Cognition announces private sale of equity securities - Investing.com
Alpha Cognition stock hits 52-week low at $5.3 amid market challenges - Investing.com Australia
Alpha Cognition Raises $52.8 Million in Stock Offering - TipRanks
Alpha Cognition Raises $52.8M in Nasdaq IPO, Strengthens Alzheimer's Drug Commercialization Plans - StockTitan
Alpha Cognition Reports Promising Data for Brain Injury Drug - TipRanks
CSE Bulletin: DelistAlpha Cognition Inc. (ACOG) - Newsfile
Alpha Cognition Announces Voluntary Delisting from CSE - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment - MSN
Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment | 2024-12-11 | Investing News - Stockhouse Publishing
Alpha Cognition Announces Positive Interim Pre-Clinical Data for Alpha-1062 Use in A Military Relevant Model of Repetitive Mild Traumatic Brain Injury - Marketscreener.com
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - BioSpace
About Us - Financial Content
Opening Day: Invizyne Technologies jumps after IPO - MSN
Alpha Cognition Inc. announced that it expects to receive $46.149996 million in funding - Marketscreener.com
Alpha Cognition announces equity offering and warrant adjustments - Investing.com
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com India
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update - Business Wire
Alpha Cognition director Leonard Mertz acquires $49,996 in shares By Investing.com - Investing.com South Africa
Alpha cognition director John Havens buys $24,995 in common shares By Investing.com - Investing.com Nigeria
Alpha Cognition director Leonard Mertz acquires $49,996 in shares - Investing.com
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 By Investing.com - Investing.com UK
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):